|Price Per Pill or Unit
|US Brand Name
Rasalect 1 mg contains the active ingredient rasagiline, a prescription treatment for Parkinson’s disease in adults. Your doctor may prescribe it as monotherapy or adjunct therapy (with levodopa) in patients with motor fluctuations. Rasalect 1 mg is used once daily with or without levodopa. Parkinson’s disease is a neurodegenerative disorder that involves the malfunction and death of vital nerve cells in the brain, called neurons. The treatment aims to alleviate symptoms through a balance of anti-cholinergic and dopaminergic drugs. Parkinson’s disease is complex due to the progressive nature of the disease. Rasagiline is the active ingredient of medicine; it is a chemical inhibitor of the enzyme monoamine oxidase (MAO); it inactivates MAO by binding to it at type B, increasing dopamine available in the central nervous system. Dopamine is the brain chemical involved in movement control. This anti-parkinsonian drug helps to increase and sustain levels of dopamine in the brain.
When Rasalect 1 mg is used as monotherapy or as an adjunct therapy in patients not taking levodopa, patients may begin taking Rasagiline formulation at the recommended dose of 1 mg administered orally once daily. The recommended doses should not be exceeded because of the risk of hypertension. People with hepatic insufficiency should consult their doctor before taking Rasalect tablets. The anti-parkinsonian drug should not be used in patients with moderate or severe hepatic impairment. If you think you may have taken too many tablets, contact your doctor right away. Symptoms of an overdose include extremely high blood pressure, slightly euphoric mood, and serotonin syndrome.
Do not take Rasalect tablets if you are allergic to Rasagiline or any other ingredients of this medicine or have severe liver problems. Rasalect 1 mg is contraindicated for use with methadone, meperidine, propoxyphene, tramadol, and MAO inhibitors because of the risk of serotonin syndrome. A gap of at least a weak should be kept between discontinuation of Rasalect and initiation of treatment with these medicines. This anti-parkinsonian drug should not be given with St. John’s wort and cyclobenzaprine. Concomitant use with dextromethorphan should also be avoided because of the risk of psychosis or bizarre behaviour. Exacerbation of hypertension may occur during the treatment. Dose adjustment is necessary if hypertension is sustained. Close monitoring is required for new-onset hypertension that is not adequately controlled. Serotonin syndrome has been reported with concomitant use of antidepressants, phenelzine, tranylcypromine, selegiline and Rasagiline. The symptoms of serotonin syndrome have included behavioural and cognitive changes, for example, hallucinations, confusion, agitation, headache, coma, and hypomania. It has been reported that falling asleep while engaged in activities of daily life always occurs.
For this reason, patients should be monitored for sleepiness or drowsiness. When sued as an adjunct to levodopa, Rasalect may cause dyskinesia dopaminergic side effects. Let your doctor know if you have liver problems or notice any signs of suspicious skin changes.
Side effects of Rasalectg 1 mg include hypertension, hypotension, dyskinesia, impulse control, serotonin syndrome, melanoma, hallucinations, falling asleep during activities of daily living, withdrawal-emergent hyperpyrexia and confusion.